GlassScriptPhysician profile
Yailin Homen
NPI 1609487792
$8,558.58
in general payments reported to CMS, 2019-2025
23 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,395 · 2022: $3,539 · 2023: $969 · 2024: $418 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296 · Education: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.76 |
| Education | $328.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,295.81 | 2021-2023 | Amjevita, Prolia, Evenity |
| Ucb, INC. | $1,049.44 | 2021-2023 | Cimzia |
| Novartis Pharmaceuticals Corporation | $1,009.30 | 2021-2024 | |
| Abbvie INC. | $964.86 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $658.78 | 2021-2023 | Acthar |
| Lilly USA, LLC | $510.71 | 2021-2023 | Taltz |
| Horizon Therapeutics Plc | $454.77 | 2021-2022 | |
| Astellas Pharma US INC | $431.16 | 2024-2025 | Cresemba |
| Janssen Biotech, INC. | $373.98 | 2022-2025 | Tremfya, Carvykti, Rybrevant |
| Aurinia Pharma U.S., INC. | $347.94 | 2021-2023 | Lupkynis |
| Pfizer INC. | $343.40 | 2021-2023 | |
| Glaxosmithkline, LLC. | $279.39 | 2021-2023 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $245.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $176.49 | 2022-2023 | Saphnelo |
| Radius Health, INC. | $120.70 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $104.77 | 2021-2023 | Orthovisc, Monovisc, Peak |
| Bioventus LLC | $60.19 | 2021-2025 | Gelsyn-3 |
| Grt US Holding, INC. | $27.39 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.46 | 2023 | Livtencity |
| Paratek Pharmaceuticals, INC. | $22.99 | 2025 | Nuzyra |
| Kiniksa Pharmaceuticals, LTD. | $20.33 | 2021 | |
| Atricure, INC. | $19.90 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yailin Homen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.